[Inhibition of acetylcholinesterases--a relevant side effect of ranitidine?].
Ranitidine inhibited in a dose-dependent manner acetylcholinesterases from human erythrocytes and gastric mucosa. The concentration for half-maximal inhibition was 1,5 X 10(-6) and 1,4 X 10(-6) mol/l, which resembles levels seen during therapy. Inhibition was of competitive type, the inhibitory constant measured 1,6 X 10(-6) mol/l. Pseudocholinesterase in serum was also inhibited, however, the levels required were about 25 times higher. As a consequence from our in vitro findings a stimulation of cholinergic mechanisms in ranitidine treatment should occur, e. g. stimulation of glandular secretion or increase of gastrointestinal motility.
D000110:Acetylcholinesterase; D000897:Anti-Ulcer Agents / Q000009:adverse effects*; D002800:Cholinesterase Inhibitors; D004305:Dose-Response Relationship, Drug; D004912:Erythrocytes / Q000187:drug effects / Q000201:enzymology; D005663:Furans / Q000009:adverse effects*; D005753:Gastric Mucosa / Q000187:drug effects / Q000201:enzymology; D006801:Humans; D011899:Ranitidine
D000897:Anti-Ulcer Agents; D002800:Cholinesterase Inhibitors; D005663:Furans; D011899:Ranitidine; D000110:Acetylcholinesterase
Hemmung der Azetylcholinesterasen--ein relevanter Nebeneffekt von Ranitidin?